Pharmaceutical USA-headquartered digital medicines company Akili Interactive today announced collaborations with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center, to evaluate Akili digital therapeutic AKL-T01 as a treatment for patients with cognitive dysfunction following COVID-19 (also known as “COVID brain fog”). There are currently no approved treatments for cognitive impairments in COVID-19 survivors. 7 April 2021